title: General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction.
abstract: OBJECTIVE
  To investigate the impact of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) on the risk of first acute myocardial infarction (MI).
  
  
  METHODS
  Case-control analysis and a self controlled case series.
  
  
  METHODS
  644 general practices throughout England, Scotland, Wales, and Northern Ireland.
  
  
  METHODS
  Over 60,000 cases of MI and 360,000 age, sex, and practice matched controls randomly selected from the UK General Practice Research Database.
  
  
  METHODS
  Matched odds ratios and incidence rate ratios estimating whether there is an acute or prolonged increased risk of MI after exposure to TCA and SSRI drugs and individual drugs within these families.
  
  
  RESULTS
  Case-control analysis found an initial increased risk of MI after TCA exposure (for example, at 1-7 days after the first dothiepin prescription: odds ratio (OR) 1.90, 95% confidence interval (CI) 1.15 to 3.14) or SSRI exposure (for example, at 1-7 days after first fluoxetine prescription: OR 2.59, 95% CI 1.44 to 4.66). In the self controlled analysis the equivalent risk estimates were an incidence rate ratio of 1.43, 95% CI 0.92 to 2.22 for dothiepin and an incidence rate ratio of 1.66, 95% CI 1.01 to 2.71 for fluoxetine.
  
  
  CONCLUSIONS
  Antidepressant prescriptions are associated with an increased risk of MI. The size of these effects is similar for TCA and SSRI exposures; however, the lack of specificity between types of antidepressants and the lower risks found in the self controlled analysis suggest that these associations are more likely due to factors relating to underlying depression and health services utilisation than to specific adverse drug effects.
authors.affiliation: Division of Epidemiology and Public Health, Clinical Sciences Building, Hucknall Road, Nottingham NG5 1PB, UK. laila.tata@nottingham.ac.uk
authors.forename: L J
authors.initials: LJ
authors.lastname: Tata
authors.forename: J
authors.initials: J
authors.lastname: West
authors.forename: C
authors.initials: C
authors.lastname: Smith
authors.forename: P
authors.initials: P
authors.lastname: Farrington
authors.forename: T
authors.initials: T
authors.lastname: Card
authors.forename: L
authors.initials: L
authors.lastname: Smeeth
authors.forename: R
authors.initials: R
authors.lastname: Hubbard
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects*; D001794:Blood Pressure; D015992:Body Mass Index; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology / Q000209:etiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D012907:Smoking / Q000009:adverse effects; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D017367:Selective Serotonin Reuptake Inhibitors